Akari Therapeutics (AKTX)

Akari Therapeutics (AKTX) Stock Price & Analysis


AKTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.14 - $1.61
Previous Close$0.16
Average Volume (3M)554.46K
Market Cap
Enterprise Value-$1.22M
Total Cash (Recent Filing)$13.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.5
Sep 27, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding101,120,000
10 Day Avg. Volume637,500
30 Day Avg. Volume554,455
Standard Deviation0.22
Financial Highlights & Ratios
Price to Book (P/B)9.24
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.07
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $0.14 and its highest was $1.61 in the past 12 months.
    What is Akari Therapeutics’s market cap?
    Currently, no data Available
    When is Akari Therapeutics’s upcoming earnings report date?
    Akari Therapeutics’s upcoming earnings report date is Sep 27, 2023 which is in 111 days.
      How were Akari Therapeutics’s earnings last quarter?
      Currently, no data Available
      Is Akari Therapeutics overvalued?
      According to Wall Street analysts Akari Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Akari Therapeutics pay dividends?
        Akari Therapeutics does not currently pay dividends.
        What is Akari Therapeutics’s EPS estimate?
        Akari Therapeutics’s EPS estimate is -$0.05.
          How many shares outstanding does Akari Therapeutics have?
          Akari Therapeutics has 101,115,840 shares outstanding.
            What happened to Akari Therapeutics’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Akari Therapeutics?
            Currently, no hedge funds are holding shares in AKTX


            Akari Therapeutics Stock Smart Score

            This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
            Learn more about TipRanks Smart Score

            Company Description

            Akari Therapeutics

            Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.


            Forecast EPS vs Actual EPS

            Currently, no data available
            Please return soon. This page is being updated.

            Similar Stocks
            Price & Change
            Arrowhead Pharmaceuticals
            Corvus Pharmaceuticals
            Fate Therapeutics

            Popular Stocks

            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis